Share Name Share Symbol Market Type Share ISIN Share Description
Abcam LSE:ABC London Ordinary Share GB00B6774699 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +15.50p +1.75% 901.00p 900.00p 900.50p 901.00p 884.00p 884.00p 662,876 16:35:05
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 171.7 45.4 18.6 48.4 1,827.39

Abcam (ABC) Latest News

More Abcam News
Abcam Takeover Rumours

Abcam (ABC) Share Charts

1 Year Abcam Chart

1 Year Abcam Chart

1 Month Abcam Chart

1 Month Abcam Chart

Intraday Abcam Chart

Intraday Abcam Chart

Abcam (ABC) Discussions and Chat

Abcam Forums and Chat

Date Time Title Posts
11/10/201622:44ABCAM with Charts & News8
10/10/201607:38Investing ? Start with your ABC's701
29/8/201323:08ABCAM - another e-Commerce Retailer120
01/9/201210:17Come On You Beauty!3

Add a New Thread

Abcam (ABC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Abcam trades in real-time

Abcam (ABC) Top Chat Posts

Abcam Daily Update: Abcam is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ABC. The last closing price for Abcam was 885.50p.
Abcam has a 4 week average price of 862.75p and a 12 week average price of 794.13p.
The 1 year high share price is 901p while the 1 year low share price is currently 547p.
There are currently 202,817,638 shares in issue and the average daily traded volume is 589,437 shares. The market capitalisation of Abcam is £1,827,386,918.38.
campbed: Very good trading update today outlining progress on all fronts. A great British success story . Share price at 640p almost back to the all time high of 660p reached at end of 2015 before the market-wide Jan sell off.
trident5: I've never seen a share price go round in a circle like that. Is that a good sign?
apad: Slater in the Telegraph today - with any luck that should drive the share price down for those who are looking for an entry point. apad  . .R01;and some can be disastrous Other Aim shares that are favourites of veteran IHT investors are Young & Co’s Brewery, Advanced Medical Solutions and Abcam. All three are good sound companies but it seems to me that their share prices are living on the memory of their excellent past growth. Nowadays their p/e ratios are in or around the 20s with only single-digit earnings growth forecast. They are not for me because the slightest upset in their earnings growth could cause a major setback in their shares.
jeffcranbounre: Abcam is featured in today's ADVFN podcast. To listen to the podcast click here> In today's podcast: - Chris Oil, financial writer and city investor will be chatting about a well known name who could be back in fashion. Chris on Twitter is @ChrisOil - And Rodney Hobson, a financial speaker, writer and author of investment books including Shares Made Simple, the beginner's guide to the stock market. Rodney on Twitter is @RodneyHobson - The micro and macro news - Plus the broker forecasts Every Tuesday is Ten Bagger Tuesday on the podcast. If you know of a stock, whose share price has the potential to increase ten fold, just click the link below. Ten Bagger Tuesday (All it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). Once a week, on a Friday, I feature a tip from a listener to this podcast, if you'd like to suggest a stock click the link below: Suggest a stock (Again all it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). You can subscribe to this podcast in iTunes by clicking HERE To follow me on Twitter click HERE As a listener to the ADVFN podcast you can take advantage of some exclusive first year discounts on popular subscriptions: Bronze - £50 (normally £73.82/year) Silver - £145 (normally £173.71/year) Level 2 - £350 (normally £472.94/year) Call 0207 0700 961 and ask for the ADVFN Podcast discount to take advantage of these reduced rates or just CLICK HERE for more information. Please DO NOT buy any stock recommended in this podcast basely solely on what you hear. The opinions in this podcasts are just that, opinions. Please do you own research before investing. Justin    
richscotsman: Abcam may well have it's ups and downs.... Look at the chart and it is mainly up. They do however have unique capability in a market which has long term grant funding... For me this is a safer bet in a downturn than gold but also okay generally. The fact that the bod take a view of future markets and invest in a company that they can add value to is positive. What may cost in the short term is wise in the long term. They could easily have made no progress by cutting overheads to a minimum in search of short term share price reward. The acquisition is further evidence of bod that understands the future market and can close a deal. Strip out currency and the growth is stunning. If you look forward then those currency trends may well reverse.
simon gordon: Unicorn AIM VCT - 20/5/14 Abcam (-23%) is a global leader in the supply of innovative protein research tools. In March 2014, Abcam released its financial results for the six month period ended 31 December 2013, which were in line with your Investment Manager's internal forecasts. Revenues of £61.9m (H2 2012: £57.3m) represented half-year on half-year growth of over 8%, while earnings per share were up 6.5% to 8.74p (H2 2012: 8.21p). Abcam remains a cash generative business with a robust balance sheet. Net cash balances at the period end amounted to £35.3m. Despite Abcam's many obvious qualities, market reaction to the release of Interim Results in early March was negative as investors worried about currency headwinds and the impact of possible cuts to health budgets in the key North American market, which accounts for 43% of total sales. As a result, Abcam's share price ended the period markedly lower. The holding has been retained in the portfolio in the expectation that the de-rating in the value of Abcam will prove to be temporary.
apad: IC Since releasing half-year results and exposing sluggish Asian sales, medical-proteins supplier Abcam (ABC) has seen its share price crash, tumbling 12 per cent on the morning the figures were first reported. While underlying sales still managed to grow 9 per cent in Japan during the six months to December, this did not live up to analysts' expectations and even Abcam was surprised, having previously identified US sequestration as the bigger threat to growth last year. But efforts will still be made to consolidate the group's position in China this year, with a new office in Shanghai due to open. Chief executive Jonathan Milner has said he is focused on 'getting it right' in Asia and subsequently picked up an extra £1m worth of new shares in the group after seeing the price fall and present a cheaper entry point. Before dropping to its current price of 383p, the shares carried a pretty punchy rating of 27, prompting us to maintain our bearish stance and recommend offloading more of the stock. Considering emerging markets remain crucial to the future growth of Abcam and certain parts of Asia are failing to meet ambitious expectations, the shares probably have further to fall. Sell. HR
richscotsman: Buy into Abcam as share price drops, says Numis Antibody supplier Abcam (ABC.L) has been upgraded from 'hold' to 'buy' by Numis analyst Charles Weston. Weston placed a target price of 510p on the shares despite a sharp drop in the share price earlier in the week as it revealed sluggish Japanese growth despite the Japanese government investing in research. 'We are upgrading our recommendation to 'buy', from 'hold', following the sharp fall in the share price [on Wednesday morning],' he said. 'In our view little has changed in the fundamental investment thesis for Abcam and history has taught us that periods of weakness in its share price are the right time to buy into its highly defensive business model.' Weston said he 'expected margins and cash generation to remain high due to the characteristics of the product and Abcam's digital platform' and that management's investment in new growth initiatives has 'yet to translate to accelerating growth rates, which could start to be delivered over the next six-12 months'.
apad: My take is that the important financial metric out of the interim is that the increase in staff will impact profits at these growth rates, which is why the share price fell so much on the announcement of the interims. As an "owner" I see this expenditure as vital to becoming dominant in a fragmented market. ABC's growth is dependent on increasing its market share in a market that is strongly dependent on government spending. The second string to this bow is, as buywell the second indicates, acquisitions. These acquisitions need to fit in with ABC's "postal" business model - there was some criticism of the last acquisition on this basis. I do not know how many sensible propositions are out there, which is where, rich's "trust in the management" kicks in. The smaller tech. component of my portfolio is predicated on the need for management to know their technology from soup to nuts and ABC fits snugly into this category. All of this I am comfortable with, but I do not have a clear idea about ABCAM's standing amongst its peers in this fragmented market, or the rate of change of its market share. Based on this narrative, my eleventh purchase will be at 08:05 on the morning of an acquisition announcement, iff the share price remains depressed. apad
billy ray: From this week's IC, just for info. Cheers Abcam's rating looking vulnerable Created:21 July 2011Written by:Julian Hofmann BULL POINTS: ■ Plenty of cash ■ Scope for dividend growth BEAR POINTS: ■ Over-valued as an internet firm ■ Lacks "scale-ability" ■ Delays to US research funding ■ Little presence in China One of the toughest decisions an investor has to make is when to call the top on a successful investment. Get out too early and further gains are lost; too late and risk giving back profits if unforeseen events hit the share price. Shares in medical services company Abcam present investors with precisely this dilemma; and it's not made any easier by Abcam's deserved reputation as a well-run company. However, shareholders who bought into Abcam five years ago would have seen their investments more than quadruple in value. That's excellent considering what has happened to the stock market indices during the same period, but ultimately that success only increases the scrutiny of Abcam's business model and its markets. The rise in value has been so impressive that Abcam's share rating now bears little relation to any company in the healthcare or medical technology sectors and has more in common with internet distribution companies, such as Amazon or Asos. That comparison is flattering and reflects the excellent niche Abcam has developed in shipping antibodies to companies and research institutes who order via an online web site. However, it may ultimately prove to be a weakness as a straight comparison of business models reveals some crucial differences. IC TIP RATING Risk rating High Timescale Short term What do these mean? Find out in our guide to tip ratings To begin with, Abcam's markets are heavily regulated, so adding products in addition to antibodies and shipping them around the world on the existing platform could run into regulatory hurdles. In contrast, Amazon can simply add a new line. This is what online retailers rather clumsily call "scale-ability" and it is an area where Abcam is comparatively deficient. Second, Abcam is exposed to the vagaries of public spending in a way that affects no other internet distribution firm. This is the single biggest worry and the signs are that delays to research grants are starting to depress demand in the huge US antibody market. Figures for US research spending compiled by broker Edison Investment Research suggest a slowdown in research grants without additional stimulus spending. The Recovery Act stimulus package, passed by Congress in 2009, accounted for a cumulative rise of $7.7bn in research grants as money flowed into disbursing bodies such as the National Institutes of Health (NIH) in 2009 and 2010. That period of spending coincides neatly with Abcam's time of greatest sales growth. But, without stimulus spending this year, NIH grants are forecast to increase by only $2.2bn to $32.2bn, Edison estimates. ABCAM (ABC) ORD PRICE: 420p MARKET VALUE: £763m TOUCH: 417-420p 12M HIGH: 470p LOW: 276p DIVIDEND YIELD: 1.5% PE RATIO: 28 NET ASSET VALUE: 33p NET CASH: £47m Year to 30 Jun Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p) 2008 36.6 8.0 3.4 1.1 2009 56.8 16.3 7.0 2.4 2010 71.1 25.8 10.8 4.0 2011* 84.4 31.8 12.9 5.3 2012* 98.6 37.4 15.1 6.5 % change +17 +18 +17 +23 Normal market size: 1,250 Matched bargain trading Beta: 0.3 Edison Investment Research forecasts More share tips and updates... While it has a big exposure to mature markets (in addition to the US, 25 per cent of its sales come from the EU), Abcam has little presence in China, where research spending is rising rapidly but profit margins are lower. Currently, Abcam generates just 4 per cent of its sales in China, so it will need to expand there rapidly to help offset the dominance of US revenues in its income statement. -------------------------------------------------------------------------------- SHARE TIP SUMMARY: SellTrue, Abcam's share price has stared from the top of mountains before only to reach higher peaks. So much so that its rating is approaching 28 times forecast earnings for 2011-12. That represents a massive premium to the healthcare sector and fails to reflect a basic risk that Abcam's sales could plateau far more quickly than the market assumes. True, the healthy cash pile could easily be used to reward investors for holding the shares, or to fund acquisitions in a fragmented sector. But, ironically, acquisition-drive growth would most likely depress the rating anyway. Meanwhile, the risks are such that it must be very tempting for those who can take fat profits to do so. Sell.
Abcam share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20161020 19:36:10